See more : Kogi Iron Limited (KFE.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Alector, Inc. (ALEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alector, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Alchemy Creative, Inc. (ALMY) Income Statement Analysis – Financial Results
- ParkerVision, Inc. (PRKR) Income Statement Analysis – Financial Results
- HomeStreet, Inc. (HMST) Income Statement Analysis – Financial Results
- Public Joint-Stock Company PhosAgro (PHOR.ME) Income Statement Analysis – Financial Results
- Toyo Drilube Co., Ltd. (4976.T) Income Statement Analysis – Financial Results
Alector, Inc. (ALEC)
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 97.06M | 133.62M | 207.09M | 21.10M | 21.22M | 27.68M | 3.74M | 416.00K |
| Cost of Revenue | 192.12M | 8.47M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| Gross Profit | -95.05M | 125.15M | 17.68M | -135.77M | -79.31M | -45.35M | -26.18M | -13.26M |
| Gross Profit Ratio | -97.93% | 93.66% | 8.54% | -643.53% | -373.76% | -163.87% | -700.83% | -3,187.02% |
| Research & Development | 192.12M | 210.42M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| General & Administrative | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Other Expenses | 0.00 | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Operating Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Cost & Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.85M | 8.47M | 8.31M | 7.27M | 5.57M | 1.02M | 680.00K | 201.00K |
| EBITDA | -142.89M | -129.36M | -29.05M | -187.91M | -109.47M | -56.27M | -32.00M | -14.93M |
| EBITDA Ratio | -147.22% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -856.73% | -3,589.18% |
| Operating Income | -151.74M | -137.83M | -37.36M | -195.17M | -114.40M | -57.29M | -32.68M | -15.13M |
| Operating Income Ratio | -156.33% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -874.94% | -3,637.50% |
| Total Other Income/Expenses | 26.56M | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Income Before Tax | -125.18M | -130.06M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Income Before Tax Ratio | -128.97% | -97.33% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3,632.21% |
| Income Tax Expense | 5.21M | 3.25M | -8.32M | -7.27M | -5.57M | 5.04M | 0.00 | 0.00 |
| Net Income | -130.39M | -133.31M | -28.01M | -182.96M | -99.81M | -52.25M | -32.48M | -15.11M |
| Net Income Ratio | -134.34% | -99.77% | -13.53% | -867.21% | -470.39% | -188.78% | -869.61% | -3,632.21% |
| EPS | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| EPS Diluted | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| Weighted Avg Shares Out | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
| Weighted Avg Shares Out (Dil) | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
Alector to Present at Upcoming Virtual Healthcare Conferences
Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021
Alector: Pioneering Approach In CNS Diseases
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Alector Reports 2021 First Quarter Financial Results and Provides Business Update
Alector to Present at Stifel's 3rd Annual CNS Day
Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday
Alector to Present at the Barclays Global Healthcare Conference
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer's Disease
Source: https://incomestatements.info
Category: Stock Reports